tradingkey.logo

Nexalin Technology Inc

NXL
0.532USD
+0.015+2.92%
交易中 美东报价延迟15分钟
3.87M总市值
亏损市盈率 TTM

Nexalin Technology Inc

0.532
+0.015+2.92%

关于 Nexalin Technology Inc 公司

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Nexalin Technology Inc简介

公司代码NXL
公司名称Nexalin Technology Inc
上市日期Sep 16, 2022
CEOWhite (Mark)
员工数量6
证券类型Ordinary Share
年结日Sep 16
公司地址1776 Yorktown
城市HOUSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编77056
电话18322600222
网址https://nexalin.com
公司代码NXL
上市日期Sep 16, 2022
CEOWhite (Mark)

Nexalin Technology Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
185.75K
+36459.00%
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+6000.00%

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%
地区USD
名称
营收
占比
International Sales
59.48K
84.26%
U.S. Sales
11.11K
15.74%
业务
地区
业务USD
名称
营收
占比
Equipment
52.53K
74.41%
Licensing Fee
10.36K
14.67%
Other
7.71K
10.92%

股东统计

更新时间: 1月31日 周六
更新时间: 1月31日 周六
持股股东
股东类型
持股股东
持股股东
占比
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
其他
86.14%
持股股东
持股股东
占比
Elson (Marilyn)
8.23%
Hu (Benjamin)
2.02%
White (Mark)
1.66%
Owens (David)
1.00%
The Vanguard Group, Inc.
0.95%
其他
86.14%
股东类型
持股股东
占比
Individual Investor
13.78%
Investment Advisor
1.59%
Hedge Fund
1.11%
Investment Advisor/Hedge Fund
0.96%
Research Firm
0.16%
Venture Capital
0.06%
其他
82.35%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
38
722.74K
3.87%
-783.30K
2025Q3
37
1.33M
7.29%
+710.60K
2025Q2
41
2.88M
16.54%
-349.86K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Elson (Marilyn)
1.54M
8.23%
--
--
Jun 04, 2025
Hu (Benjamin)
377.10K
2.02%
+36.46K
+10.70%
Sep 29, 2025
White (Mark)
309.13K
1.66%
--
--
Jun 04, 2025
Owens (David)
185.75K
1%
+36.46K
+24.42%
Sep 29, 2025
The Vanguard Group, Inc.
176.58K
0.95%
+16.70K
+10.45%
Sep 30, 2025
MYDA Advisors LLC
150.00K
0.8%
-650.00K
-81.25%
Sep 30, 2025
Geode Capital Management, L.L.C.
121.82K
0.65%
+5.45K
+4.69%
Sep 30, 2025
Kazden (Alan)
83.13K
0.45%
--
--
Jun 04, 2025
Susquehanna International Group, LLP
62.50K
0.34%
+62.50K
--
Sep 30, 2025
Renaissance Technologies LLC
55.70K
0.3%
+9.36K
+20.19%
Sep 30, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI